-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 15th, starting from the centralized procurement in 11 cities in 2018, the state-level centralized procurement has been carried out 4 times, and the fifth centralized procurement is about to be launched
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
The national centralized procurement of Chinese patent medicines and biological products has not yet started, and the provincial centralized procurement will become a pilot point for the implementation of Chinese patent medicines and biological products
.
.
In 2021, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs" mentioned "improving the alliance procurement mechanism"-"promoting the establishment of a regional and national alliance procurement mechanism
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
Since 2020, a variety of different alliance regions have been implementing centralized drug purchases
.
.
The "net" of the alliance is getting bigger and bigger,
And the mistracking is complicated
In April 2021, the Shanxi Provincial Medical Insurance Bureau of the Beijing-Tianjin-Hebei medical insurance bureaus in the alliance area will carry out the "3+N" alliance drug joint procurement in Tianjin for 11 commonly used drugs such as hypertension and diabetes
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
On November 20, 2020, the "six provinces and two districts" inter-provincial alliance drug centralized and volume procurement started
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
On April 27, 2021, the "Announcement of the "Eight Provinces and Two Districts" Medical Security Bureau on the Development of the Inter-provincial Union Drug Centralized Procurement Work" was released, and the "Eight Provinces and Two Districts" Union led by Heilongjiang revealed the number of procured products Shui Nian, among the 21 purchased varieties involved, except for felodipine oral regular-release dosage forms and calcitriol oral regular-release dosage forms, the other 19 varieties are injections, including natural medicine injection Tian/ma/su
.
.
In the "Chongqing, Eqiong, Dianqingning, New Xinjiang Corps Common Drugs Alliance Procurement Documents" and the "Chongqing, Guiqiong, Yunnan, Qingning, Ningxia New Xinjiang Corps Shortage Drugs Alliance Guarantee Supply and Stable Price and Quantity Procurement Documents", commonly used drugs involve 35 Chemical medicine, shortage medicine involves 21 chemical medicines
.
.
On April 27, the "2+N" Alliance Drug Centralized Procurement Document of the Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region" was released, which clearly pointed out the alliance's centralized procurement area and procurement rules
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
To sum up, the provinces in the East China region still do not have the "Bao Tuan" coalition centralized procurement, but the product homogeneity of the coalition centralized procurement is very serious, and Ningxia, Qinghai, Shanxi, Xinjiang and other provinces basically go to the coalition centralized procurement.
"To join in" is to get the lowest price of the alliance's collection
.
"To join in" is to get the lowest price of the alliance's collection
.
The Sixteen Provinces Union of Guangdong:
Centralized procurement of traditional Chinese medicine in half of the provinces of the country
In April 2021, Guangdong took the lead in the centralized procurement of 16 provincial alliances, involving 362 products, including 63 Chinese patent medicines
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
image
At present, the rules for the centralized procurement of the 16-province alliance in Guangdong have not been officially announced
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
As a result, the industry is very worried that the Guangdong Sixteen Provinces Alliance will "replace prices by volume" to require companies to significantly reduce prices
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
Raw material price increases,
Quotations for centralized procurement of Chinese medicine must be rational
Most people take a pessimistic attitude towards the centralized procurement of 16 provincial-level alliances led by Guangdong, and believe that the price of a single product must be lowered
.
.
Since 2021, the cost of many raw materials has increased
.
.
For example, in 2021, the domestic paper industry announced a comprehensive price increase
.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
In medicine costs are rising
.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
On the other hand, although China's wild medicinal resources are extremely rich, due to long-term indiscriminate harvesting and hunting, wild resources have been shrinking, and their prices have been rising due to sharp declines in production
.
.
Since 2020, due to the help of Chinese medicine to prevent and control the epidemic, market demand has grown against the trend
.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
On May 24, the official website of the State Food and Drug Administration released an article on "Convening a special promotion meeting for the supervision of selected drugs in centralized procurement", which also mentioned that holders should make rational quotes to maintain the order and sustainability of orderly competition in the industry.
Development environment
.
Development environment
.
The notable case is the centralized procurement of drugs from the inter-provincial alliance of cephalexin capsules organized by Guangdong Province not long ago
.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
The centralized procurement is divided into 3 types of purchase orders
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
The bid was opened on April 9th, and Hunan Kelun planned to win the bid for the oral regular-release dosage form of cephalexin.
The winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
The winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
It can be seen that although the centralized procurement of traditional Chinese medicine is about to start, the rules of the Guangdong Pharmaceutical Trade Center may not necessarily be to pursue a substantial price reduction
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
Medical Network News, June 15th, starting from the centralized procurement in 11 cities in 2018, the state-level centralized procurement has been carried out 4 times, and the fifth centralized procurement is about to be launched
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
The national centralized procurement of Chinese patent medicines and biological products has not yet started, and the provincial centralized procurement will become a pilot point for the implementation of Chinese patent medicines and biological products
.
.
In 2021, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs" mentioned "improving the alliance procurement mechanism"-"promoting the establishment of a regional and national alliance procurement mechanism
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
Since 2020, a variety of different alliance regions have been implementing centralized drug purchases
.
.
The "net" of the alliance is getting bigger and bigger,
And the mistracking is complicated
In April 2021, the Shanxi Provincial Medical Insurance Bureau of the Beijing-Tianjin-Hebei medical insurance bureaus in the alliance area will carry out the "3+N" alliance drug joint procurement in Tianjin for 11 commonly used drugs such as hypertension and diabetes
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
On November 20, 2020, the "six provinces and two districts" inter-provincial alliance drug centralized and volume procurement started
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
On April 27, 2021, the "Announcement of the "Eight Provinces and Two Districts" Medical Security Bureau on the Development of the Inter-provincial Union Drug Centralized Procurement Work" was released, and the "Eight Provinces and Two Districts" Union led by Heilongjiang revealed the number of procured products Shui Nian, among the 21 purchased varieties involved, except for felodipine oral regular-release dosage forms and calcitriol oral regular-release dosage forms, the other 19 varieties are injections, including natural medicine injection Tian/ma/su
.
.
In the "Chongqing, Eqiong, Dianqingning, New Xinjiang Corps Common Drugs Alliance Procurement Documents" and the "Chongqing, Guiqiong, Yunnan, Qingning, Ningxia New Xinjiang Corps Shortage Drugs Alliance Guarantee Supply and Stable Price and Quantity Procurement Documents", commonly used drugs involve 35 Chemical medicine, shortage medicine involves 21 chemical medicines
.
.
On April 27, the "2+N" Alliance Drug Centralized Procurement Document of the Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region" was released, which clearly pointed out the alliance's centralized procurement area and procurement rules
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
To sum up, the provinces in the East China region still do not have the "Bao Tuan" coalition centralized procurement, but the product homogeneity of the coalition centralized procurement is very serious, and Ningxia, Qinghai, Shanxi, Xinjiang and other provinces basically go to the coalition centralized procurement.
"To join in" is to get the lowest price of the alliance's collection
.
"To join in" is to get the lowest price of the alliance's collection
.
The Sixteen Provinces Union of Guangdong:
Centralized procurement of traditional Chinese medicine in half of the provinces of the country
In April 2021, Guangdong took the lead in the centralized procurement of 16 provincial alliances, involving 362 products, including 63 Chinese patent medicines
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
image
At present, the rules for the centralized procurement of the 16-province alliance in Guangdong have not been officially announced
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
As a result, the industry is very worried that the Guangdong Sixteen Provinces Alliance will "replace prices by volume" to require companies to significantly reduce prices
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
Raw material price increases,
Quotations for centralized procurement of Chinese medicine must be rational
Most people take a pessimistic attitude towards the centralized procurement of 16 provincial-level alliances led by Guangdong, and believe that the price of a single product must be lowered
.
.
Since 2021, the cost of many raw materials has increased
.
.
For example, in 2021, the domestic paper industry announced a comprehensive price increase
.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
In medicine costs are rising
.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
On the other hand, although China's wild medicinal resources are extremely rich, due to long-term indiscriminate harvesting and hunting, wild resources have been shrinking, and their prices have been rising due to sharp declines in production
.
.
Since 2020, due to the help of Chinese medicine to prevent and control the epidemic, market demand has grown against the trend
.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
On May 24, the official website of the State Food and Drug Administration released an article on "Convening a special promotion meeting for the supervision of selected drugs in centralized procurement", which also mentioned that holders should make rational quotes to maintain the order and sustainability of orderly competition in the industry.
Development environment
.
Development environment
.
The notable case is the centralized procurement of drugs from the inter-provincial alliance of cephalexin capsules organized by Guangdong Province not long ago
.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
The centralized procurement is divided into 3 types of purchase orders
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
The bid was opened on April 9th, and Hunan Kelun planned to win the bid for the oral regular-release dosage form of cephalexin.
The winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
The winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
It can be seen that although the centralized procurement of traditional Chinese medicine is about to start, the rules of the Guangdong Pharmaceutical Trade Center may not necessarily be to pursue a substantial price reduction
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
Medical Network News, June 15th, starting from the centralized procurement in 11 cities in 2018, the state-level centralized procurement has been carried out 4 times, and the fifth centralized procurement is about to be launched
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
.
At present, for those included in the scope of centralized procurement, the number of product manufacturers that have passed the consistency evaluation still meets the conditions of "full competition" (more than or equal to 3 production enterprises)
.
The national centralized procurement of Chinese patent medicines and biological products has not yet started, and the provincial centralized procurement will become a pilot point for the implementation of Chinese patent medicines and biological products
.
.
In 2021, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs" mentioned "improving the alliance procurement mechanism"-"promoting the establishment of a regional and national alliance procurement mechanism
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
.
Centralized drug procurement agencies in the alliance Jointly set up a cross-regional joint procurement office to implement centralized drug procurement on behalf of medical institutions in the alliance region, and organize and supervise the implementation of procurement results
.
"
Since 2020, a variety of different alliance regions have been implementing centralized drug purchases
.
.
The "net" of the alliance is getting bigger and bigger,
The "net" of the alliance is getting bigger and bigger, And the mistracking is complicated
And the mistracking is complicated In April 2021, the Shanxi Provincial Medical Insurance Bureau of the Beijing-Tianjin-Hebei medical insurance bureaus in the alliance area will carry out the "3+N" alliance drug joint procurement in Tianjin for 11 commonly used drugs such as hypertension and diabetes
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
.
20 products from 18 companies were selected, with an average price drop of 71.
46%
.
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
The formation of the inter-provincial alliance involves a total of 13 varieties
.
Among them, there are natural medicine injections such as Tian/Ma/Su, puerarin and Ginkgo biloba extract, but they are all chemical medicine approvals
.
On November 20, 2020, the "six provinces and two districts" inter-provincial alliance drug centralized and volume procurement started
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
.
"Six provinces and two districts" refer to Liaoning Province, Jilin Province, Heilongjiang Province, Sichuan Province, Hainan Province, Shanxi Province, Tibet Autonomous Region and Inner Mongolia Autonomous Region, involving 17 products, mostly chemical injections
.
On April 27, 2021, the "Announcement of the "Eight Provinces and Two Districts" Medical Security Bureau on the Development of the Inter-provincial Union Drug Centralized Procurement Work" was released, and the "Eight Provinces and Two Districts" Union led by Heilongjiang revealed the number of procured products Shui Nian, among the 21 purchased varieties involved, except for felodipine oral regular-release dosage forms and calcitriol oral regular-release dosage forms, the other 19 varieties are injections, including natural medicine injection Tian/ma/su
.
.
In the "Chongqing, Eqiong, Dianqingning, New Xinjiang Corps Common Drugs Alliance Procurement Documents" and the "Chongqing, Guiqiong, Yunnan, Qingning, Ningxia New Xinjiang Corps Shortage Drugs Alliance Guarantee Supply and Stable Price and Quantity Procurement Documents", commonly used drugs involve 35 Chemical medicine, shortage medicine involves 21 chemical medicines
.
.
On April 27, the "2+N" Alliance Drug Centralized Procurement Document of the Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region" was released, which clearly pointed out the alliance's centralized procurement area and procurement rules
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
.
The alliance is led by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, and unites medical institutions in Shaanxi, Gansu, Qinghai, Ningxia, Guangxi and other provinces.
A total of 53 varieties are planned to be selected
.
Wherein group A quasi species selected 12, 41 Group B intends to select varieties
.
Among 53 varieties, 28 are injections
.
To sum up, the provinces in the East China region still do not have the "Bao Tuan" coalition centralized procurement, but the product homogeneity of the coalition centralized procurement is very serious, and Ningxia, Qinghai, Shanxi, Xinjiang and other provinces basically go to the coalition centralized procurement.
"To join in" is to get the lowest price of the alliance's collection
.
"To join in" is to get the lowest price of the alliance's collection
.
The Sixteen Provinces Union of Guangdong:
The Sixteen Provinces Union of Guangdong: Centralized procurement of traditional Chinese medicine in half of the provinces of the country
Centralized procurement of traditional Chinese medicine in half of the provinces of the country In April 2021, Guangdong took the lead in the centralized procurement of 16 provincial alliances, involving 362 products, including 63 Chinese patent medicines
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
.
This means that the centralized procurement of Chinese patent medicine provinces and regions is about to start
.
image
image At present, the rules for the centralized procurement of the 16-province alliance in Guangdong have not been officially announced
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
.
However, since the alliance basically covers half of the provinces in the country, Chinese medicine companies, especially manufacturers of exclusive Chinese medicines, must apply for the bid to keep the market
.
As a result, the industry is very worried that the Guangdong Sixteen Provinces Alliance will "replace prices by volume" to require companies to significantly reduce prices
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
.
Moreover, Guangdong's rules are very likely to be like the "4+7" of the year, and the rules for the centralized procurement of Chinese patent medicines will be extended to the whole country
.
Raw material price increases,
Raw material price increases, Quotations for centralized procurement of Chinese medicine must be rational
Quotations for centralized procurement of Chinese medicine must be rational Most people take a pessimistic attitude towards the centralized procurement of 16 provincial-level alliances led by Guangdong, and believe that the price of a single product must be lowered
.
.
Since 2021, the cost of many raw materials has increased
.
.
For example, in 2021, the domestic paper industry announced a comprehensive price increase
.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
Medicine, medicine, medicine.
Recently, the prices of cultural paper and packaging paper have increased.
The price of cultural paper has risen from 6,500 yuan/ton to 13,000-14,000 yuan/ton, which means that packaging costs are rising
.
The rising raw materials also include the prices of commodities such as copper, aluminum, steel, and plastics.
The cost increase of the entire pharmaceutical industry will be affected by the world economic cycle
.
Under such a background, only requiring the pharmaceutical industry to reduce prices but not allowing the pharmaceutical industry to increase prices may make it difficult for pharmaceutical companies to sustainably develop
.
In medicine costs are rising
.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
Herbs medicinal herbs.
With the implementation of the 2020 version of the Pharmacopoeia, Chinese medicine companies will face high standards for heavy metal and pesticide residue inspection.
The hardware of the company must be upgraded, which corresponds to the increase in testing costs
.
On the other hand, although China's wild medicinal resources are extremely rich, due to long-term indiscriminate harvesting and hunting, wild resources have been shrinking, and their prices have been rising due to sharp declines in production
.
.
Since 2020, due to the help of Chinese medicine to prevent and control the epidemic, market demand has grown against the trend
.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
Medicine Medicine Medicine.
However, some imported medicinal materials have also caused tight supply due to the epidemic
.
For example, peppermint is the most imported medicinal material produced in India.
From the perspective of domestic production and demand, there is a large gap between supply and demand for peppermint.
In the short term, there will be no supplementary imports from India, and the price of peppermint will continue to rise
.
In addition, the demand for many Chinese medicinal materials with the same food and medicine has increased significantly under the influence of the epidemic.
Moreover, due to the need for epidemic prevention and control, the country strictly controls the customs clearance and inspection links, making it more difficult to import Chinese medicinal materials
.
On May 24, the official website of the State Food and Drug Administration released an article on "Convening a special promotion meeting for the supervision of selected drugs in centralized procurement", which also mentioned that holders should make rational quotes to maintain the order and sustainability of orderly competition in the industry.
Development environment
.
Development environment
.
The notable case is the centralized procurement of drugs from the inter-provincial alliance of cephalexin capsules organized by Guangdong Province not long ago
.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
Procurement Purchasing Procurement.
The alliance regions where cephalexin drugs participated in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan did not report the volume but implemented the selected results
.
The centralized procurement is divided into 3 types of purchase orders
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
.
For oral normal-release dosage forms (including oral liquids, granules, effervescent tablets), generic drugs, original research drugs and reference preparations that have passed the consistency evaluation are included in the Class 1 A purchase order, and generic drugs that have not passed the consistency evaluation Included in Class 1 B purchase order
.
The sustained-release and controlled-release dosage form products that have not passed the consistency evaluation are included in the Class 2 B purchase order
.
The winning results are formed by their respective bidding methods
.
The Pharmaceutical Alliance only limits the price of the proposed selection of the 2 type B purchase order, and the price of each 0.
25g tablet shall not be higher than 0.
42 yuan, and there is no price limit for oral regular-release dosage forms
.
The bid was opened on April 9th, and Hunan Kelun planned to win the bid for the oral regular-release dosage form of cephalexin.
The winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
Enterprise business enterpriseThe winning price was 0.
1489/capsule
.
The sustained and controlled release dosage form is proposed to be selected by Jiangsu Hausen, and the selected price is 0.
39 yuan
.
Cephalexin capsules second batch of selected national mining company is in Hebei North China Pharmaceutical China and China Pharmaceutical, the specification is 0.
25g * 60 tablets, selected price of 5.
11 yuan, corresponding to the minimum unit of 0.
0852 yuan / tablets
.
This means that the price of cephalexin has risen instead of falling in this coalition organized by Guangdong
.
It can be seen that although the centralized procurement of traditional Chinese medicine is about to start, the rules of the Guangdong Pharmaceutical Trade Center may not necessarily be to pursue a substantial price reduction
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
.
Companies should also estimate from a cost perspective, such as channel costs reduced or exempted after centralized procurement, and reasonable quotations
.
